Ticlopidine Ginkgo biloba

Clinically important, potentially hazardous interactions with amprenavir, aprepitant, bedomethasone, buprenorphine, calcium, chloramphenicol, cimetidine, dobazam, clorazepate, cyclosporine, cyproterone, darunavir, dasatinib, delavirdine, dexamethasone, diazoxide, disulfiram, dopamine, fesoterodine, fluconazole, flunisolide, fluoxetine, fosamprenavir, ginkgo biloba, hydrocortisone, imatinib, indinavir, influenza vaccines, isoniazid, isradipine, itraconazole, lacosamide, lapatinib, lopinavir, meperidine, methylprednisolone, midazolam, mivacurium, nelfinavir, nilotinib, nilutamide, phenylbutazone, piracetam, posaconazole, prednisolone, prednisone, primrose, ritonavir, rivaroxaban, sage, saquinavir, solifenacin, St John s wort, sucralfate, telithromycin, temsirolimus, teniposide, ticlopidine, tizanidine, tolvaptan, triamcinolone, uracil/tegafur, vigabatrin... 

Ginkgo biloba has been associated with platelet, bleeding and clotting disorders and there are isolated reports of serious adverse reactions after its concurrent use with antiplatelet drugs such as aspirin, clopidogrel and ticlopidine. An animal study su ests that Kangen-Katyu may also enhance the antiplatelet and antithrombotic effects of ticlopidine. 

Kim, B.H., K.P. Kim, K.S. Lim, et al. 2010. Influence of Ginkgo biloba extract on the pharmacodynamic effects and pharmacokinetic properties of ticlopidine An open-label, randomized, two-period, two-treatment, two-sequence, single-dose crossover study in healthy Korean male volimteers. Clin. Ther. 32(2) 380-390. 

---